Home › Liver Cancer (Hepatocellular Carcinoma) › New York › New York City
Liver Cancer (Hepatocellular Carcinoma) clinical trials in New York City, NY
24 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of ZW251 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RecruitingPhase 1/2
- Research Facility, New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RecruitingObservational study
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RecruitingPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecruitingPhase 1
- New York Cancer & Blood Specialists, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RecruitingPhase 3
- Mount Sinai Hospital, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
RecruitingPhase 4
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RecruitingPhase 1
- Clinical Trial Site, New York
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
- VA NY Harbor Healthcare System, New York, NY, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA04-0, New York
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center - New York, New York
HOPE Against Cancer Recurrence in HCC
RecruitingPhase 4
- Rutgers New Jersey Medical School (New York), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
The Dragon PLC Trial (DRAGON-PLC)
Recruiting
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Liver Cancer (Hepatocellular Carcinoma) trials in other cities
- Houston, TX31 studies
- Dallas, TX19 studies
- Los Angeles, CA19 studies
- Boston, MA18 studies
- Cleveland, OH18 studies
- Chicago, IL16 studies
- Philadelphia, PA16 studies
- Pittsburgh, PA15 studies
- San Francisco, CA14 studies
- Orange, CA14 studies
- Jacksonville, FL14 studies
- San Antonio, TX13 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.